Travelan Revenue Grows Significantly in US and Australia
Filed with ASX · · 2 pages · English
Earlier from Immuron
- US Defence Depart Report-Travelan Targets Priority Pathogens
- Immuron to Receive $2.16M R&D Tax Concession Cash Refund
- Immuron Granted US Patent for NASH Treatment
- Immuron Successfully Completes NASH Phase II Clinical Study
- Travelan Experiences Strong Q1 FY2018 Sales Growth
Later from Immuron
- Appendix 4D - Half Year Financial Report - 31 Dec 2017
- Correction to False and Misleading News Release
- Immuron Reports Positive Results in NASH Clinical Trial
- Immuron Announces A$5.1M Private Placement to U.S. Fund
- Travelan Sales Continue to Soar in Third Quarter of FY2018
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron